comparemela.com

Latest Breaking News On - Mash 2023 - Page 7 : comparemela.com

Mitapivat Maintains Safety, Tolerability Over 2 Years in Sickle Cell Disease

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.

San diegoUnited statesNational institutes of healthSickle cell branch of the national heartLung blood instituteAmerican society of hematologySwee lay theinAmerican societyNational institutesSickle cell branchNational heartBlood instituteSickle cell diseaseSickle cellPhase 1Mash 2023

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre goyJohn theurer cancer centerHackensack meridian health oncology care transformation servicesHackensack university medical centerLymphoma divisionAsh annual meeting and expositionOnclive tvMantle cell lymphomaMash 2023

Dr Jennifer Brown: Zanubrutinib Efficacy Holds Up at ALPINE 39-Month Follow-Up in R/R CLL

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (r/r CLL) at 39 months of follow-up.

United statesJenniferr brownAmerican society of hematology annual meeting expositionChronic lymphocytic leukemiaHematologic malignanciesDana farber cancer instituteAmerican societyHematology annual meetingZanubrutinib vs ibrutinibJennifer brown interviewMash 2023American society of hematology

Sickle Cell Trait Linked to Increased Leukemia Risk

New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.

San diegoUnited statesDanbury hospitalOleg sostinNational inpatient sampleAmerican society of hematologyAmerican societySickle cellMash 2023

WTT Singapore Smash to return next March

BEIJING, Sept. 13 (Xinhua) World Table Tennis (WTT) on Tuesday announced plans for the 2023 edition of the WTT Singapore Smash, with a wider range of partici

Chen mengTable tennisFan zhendongGrand smashSingapore smashThe wttWill increaseCompetitions willThe 2023Tt singaporeNd theMash 2023

vimarsana © 2020. All Rights Reserved.